Nomogram based on inflammation-related markers for predicting survival of patients undergoing hepatectomy for hepatocellular carcinoma

Figure 1  The flowchart of the study cohort.

Figure 2 Kaplan–Meier survival curves of predictor stratification for overall survival in the training cohort. Median overall survival (stratification, months): neutrophil-to-lymphocyte ratio (low, 42; high, 28), platelet-to-lymphocyte ratio (low, 40; high, 28), α-fetoprotein (< 400 μg/L, 37; ≥ 400 μg/L, 29), tumour size (< 5 cm, 38; ≥ 5 cm, 30), grade (well, 36; moderate, 32; poor, 30), and lymph node metastasis (no, 34; yes, 29). NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; AFP: Alpha-fetoprotein; LNM: Lymph node metastasis.

Figure 3 Nomogram for predicting OS in the training cohort. NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; AFP: Alpha-fetoprotein; OS: Overall survival.

Figure 4 Screenshot of the online dynamic calculator to predict OS of hepatocellular carcinoma patients after hepatectomy. NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; AFP: Alpha-fetoprotein; OS: Overall survival.

Figure 5  Calibration curves for predicting 1-, 2- and 3-year overall survival in the training cohort (A–C) and validation cohort (D–F).

Figure 6  Receiver operating characteristic curves for predicting 1-, 2- and 3-year overall survival in the training cohort (A–C) and validation cohort (D–F).